Skip to main content
Premium Trial:

Request an Annual Quote

EliTech to Distribute Curetis Unyvero Products in Belgium, Luxembourg

NEW YORK (GenomeWeb News) – Molecular diagnostics company Curetis today announced a deal with EliTech BNL to distribute its products in Belgium and Luxembourg.

Terms of the deal were not disclosed.

EliTech BNL, formerly call Lucron Bioproducts, is part of the EliTech Group and supported Cepheid's entry into the Benelux market, Curetis said.

"Having built a successful business for Cepheid and the GeneXpert system in the Benelux, we are excited about the opportunity presented by the Curetis Unyvero Solution," Frank Loots, general manager of EliTech BNL, said in a statement. "We are planning a commercial rollout and market introduction phase here in Belgium and in Luxembourg to begin with leading clinicians and institutions in our territories."

Curetis' PCR-based Unyvero System enables DNA-based testing for the detection of a broad panel of bacteria and antibiotic resistance from a single sample in one run. The first CE-marked Unyvero Cartridge simultaneously analyzes 39 DNA targets for pneumonia testing, and another Unyvero application for implant and tissue infections is in product development, Curetis said.

The Holzgerlingen, Germany-based company said in December it anticipates filing a 510(k) application with the US Food and Drug Administration for the Unyvero System in 2014 and began a clinical trial for the platform and its lower respiratory tract application.

Curetis today also announced it has hired Helmut Hilbert as head of business development. Hilbert was formerly with Qiagen.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.